(ADLR: News ) is jumping 135 percent to $4.51 as it agreed to be acquired by Cubist Pharmaceuticals, Inc. (CBST) for $4.25 per share in cash, or approximately $190 million on a...(read more
Exelixis (EXEL) is at the ASCO conference in Chicago and over the weekend, they released phase II study results for CABO and its effects on ovarian cancer. Monday afternoon, they will be...(read more
It has been a while since I put together chart analysis for biotechnology company Exelixis (EXEL), so I made it a point to do this before the market opens on Monday.
EXEL is in a clear downtrend that did breach the bottom of the trading range for one day and bounced on Friday along with [...]